Corcept Gains FDA Approval for Ovarian Cancer Drug Lifyorli

Edgen Stock·Mar 25 2026, 17:21

Share to

Share to

Copy link

Key Takeaways

Corcept Therapeutics has secured U.S. Food and Drug Administration (FDA) approval for its drug Lifyorli, positioning the company to enter the market for platinum-resistant ovarian cancer. The approval, announced on March 25, 2026, validates the company's cortisol-modulating drug development platform and opens a significant new revenue channel.

FDA Approval: The FDA approved Lifyorli (relacorilant) for adults with platinum-resistant epithelial ovarian cancer.
Combination Therapy: The treatment is approved for use in combination with the chemotherapy drug nab-paclitaxel.
Commercial Milestone: This regulatory green light allows Corcept to commercialize a new product, representing a major catalyst for future revenue growth.

FDA Greenlights Lifyorli on March 25 for Difficult-to-Treat Cancer

The U.S. Food and Drug Administration (FDA) officially approved Corcept Therapeutics' drug Lifyorli on March 25, 2026. The drug, scientifically known as relacorilant, is a selective glucocorticoid receptor antagonist designed to treat adults with platinum-resistant epithelial ovarian cancer. This approval specifically applies when Lifyorli is used in combination with the chemotherapy agent nab-paclitaxel, offering a new therapeutic strategy for a patient population with limited options.

Approval Unlocks New Commercial Pathway for Corcept

This regulatory decision marks a pivotal commercial milestone for Corcept Therapeutics, transforming Lifyorli from a development-stage asset into a revenue-generating product. The approval validates the company's scientific approach, which focuses on developing medications that modulate the effects of the hormone cortisol to treat severe disorders. For investors, the event signals a clear path to market entry and future revenue growth, establishing a new foothold for the company in the competitive oncology space.